Drug Profile
Research programme: selective estrogen receptor modulators - Forendo Pharma
Alternative Names: hotflushSERM™Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator QuatRx Pharmaceuticals
- Developer Forendo Pharma
- Class
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Menopausal syndrome
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Menopausal-syndrome in Finland
- 12 Jul 2013 Forendo Pharma acquires selective estrogen receptor modulators programme from QuatRx Pharmaceuticals
- 04 Apr 2008 Preclinical development is ongoing